BRAF and thyroid gland carcinoma: We present the health-related quality of life (HR-QoL) outcomes from the trial.<h4>Methods</h4>The multicenter, open-label, uncontrolled phase 2 trial enrolled patients with unresectable locally advanced or metastatic BRAF V600E-mutated thyroid cancer.